The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2006Treatment of Parkinson’s Disease with AT2101, a compound that increases the activity of endogenous Glucocerebrosidase
Genetic association studies have suggested a link between Parkinson's and Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the gene GBA, which results in a loss...
-
Therapeutics Development Initiative, 2006PN277: A NEURO- RESTORATIVE, PROTECTIVE PRODUCT FOR PARKINSON’S DISEASE
Acute and chronic neurodegenerative disorders such as Parkinson's disease, stroke, head trauma, spinal cord injury, Huntington's, Alzheimer's and ALS affect millions of people worldwide. Currently...
-
Therapeutics Development Initiative, 2006Develop Engineered Zinc Finger Protein Transcriptional Activators of the Glial Cell Line-Derived Neurotrophic Factor (GDNF) Gene as a Potential Therapy for Parkinson's Disease
Engineered zinc finger protein transcription factors (ZFP TFs) are an emerging class of molecules with the potential for broad therapeutic impact in the treatment of human disease. ZFP TFs function by...
-
Rapid Response Innovation Awards, 2007Nanoparticle Gene Therapy for Parkinson's Disease
In this research project we will determine the feasibility of condensing plasmid DNA into nanoparticles and using these nanoparticles to deliver their payload into cells of the central nervous system...
-
Rapid Response Innovation Awards, 2007A Novel Strategy for the Selection and Transplantation of Dopamine-Specified Human Embryonic Stem Cells
In Parkinson’s disease (PD), neurodegeneration is largely confined to one discrete group of nerve cells that produce the chemical dopamine (DA). Since the death of most DA neurons almost always...
-
Community Fast Track, 2005Specific Inhibition of Nucleation of Alpha-synuclein Aggregation as a Therapeutic Strategy
There is considerable evidence that aggregates of the human brain protein alpha-synuclein are a primary cause of the loss of neurons in Parkinson's disease. We have tried to find out what initiates...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.